3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Endometrial Neoplasms
15
Ovarian Neoplasms
5
Uterine Cervical Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Breast Neoplasms
4
Endometrial Hyperplasia
3
Pancreatic Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Kidney Neoplasms
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Interventions
Fulvestrant
2
serabelisib
1
sapanisertib
1
ribociclib
1
palbociclib
1
olaparib
1
niraparib
1
inavolisib
1
exemestane
1
capivasertib
1
abemaciclib
1
Tamoxifen
1
STX-478
1
Paclitaxel
1
Metformin
1
Letrozole
1
Irinotecan
1
Imlunestrant
1
Gemcitabine
1
CYH33
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Metformin
×
Gynecologic
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled